The Global Canine Atopic Dermatitis Treatment Drugs Market Growth is Propelled by rising pet adoption
Canine atopic dermatitis is a chronic allergic skin condition seen in dogs. Symptoms include itching, redness, swelling, hair loss, hot spots, and skin infections. Canine atopic dermatitis treatment drugs help in managing symptoms and improving quality of life in dogs. These drugs are available in forms such as injections, sprays, and powders. With rising pet ownership and humanization of pets, concerns regarding pet health and well-being have increased considerably. Owners are more willing to spend on advanced treatment options to provide relief to their pets suffering from skin issues.
The global Canine Atopic Dermatitis Treatment Drugs Market is estimated to be valued at US$ 1.2 billion in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
People nowadays consider pets as integral family members and do not hesitate to spend on their healthcare. This has increased demand for innovative drugs that can effectively manage symptoms of atopic dermatitis in dogs and improve their quality of life. Pet owners actively look for advanced treatment options and work closely with veterinarians to select the best medication as per their pet's needs. This focus on pet wellness continues to drive revenue opportunities for drugs combating canine atopic dermatitis condition.
Segment Analysis
The global canine atopic dermatitis treatment drugs market can be segmented based on treatment, drug type, animal type, route of administration, distribution channel and region. On the basis of treatment, the market is segmented into antihistamines, corticosteroids, immune-suppressants, antiseptics & antibiotics, omega-3 fatty acid inhibitors and others. Currently, corticosteroids dominate the market as they are the first line of treatment for atopic dermatitis in dogs. However, other alternatives are also being explored due to the side-effects associated with long-term use of corticosteroids.
Key Takeaways
The Global Canine Atopic Dermatitis Treatment Drugs Market Size is expected to witness high growth over the forecast period. Rising pet ownership and growing expenditure on pet healthcare are some of the key factors driving market growth. According to recent estimates, over 20-30% of dogs suffer from atopic dermatitis at some point in their lifetime. With rising awareness regarding the condition and availability of new treatment options, the demand for prescription drugs and therapies is increasing. The global Canine Atopic Dermatitis Treatment Drugs Market is estimated to be valued at US$ 1.2 billion in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.
Regional analysis:
North America accounts for the largest share of the global market currently due to high pet healthcare expenditure and high diagnosis rates in the region. The United States is home to over 180 million pet dogs and this number is increasing annually. Availability of advanced veterinary healthcare facilities and growing adoption of novel treatment options are fueling market expansion in the region.
Key players:
Key players operating in the canine atopic dermatitis treatment drugs market are Zoetis, Virbac, Elanco Animal Health, Bayer, and Dechra Pharmaceuticals. Zoetis dominates the global canine atopic dermatitis market with its portfolio of antihistamines and topical drugs used for treating canine atopic dermatitis. Elanco Animal Health offers Cytopoint, an injectable monoclonal antibody therapy that provides itch relief for several months with a single dose.
For More details on the topic:
Comments
0 comment